Why the study?
Do beta-blockers reduce cardiac mortality and morbidity in patients undergoing non-cardiac surgery?
Do beta-blockers reduce cardiac mortality and morbidity in patients undergoing non-cardiac surgery?
The protective effect of beta-blockers in perioperative medicine may depend on the surgical risk class, offering potential mortality benefits specifically in high-risk non-cardiac surgery.
Myocardial ischemia is a relatively frequent complication in patients undergoing non-cardiac surgery and β-blockers may have a protective effect. β-blockers reduce the oxygen supply:demand ratio, and exert anti-inflammatory and anti-arrhythmic effects. However, randomized trials, specifically conducted to test this hypothesis, yielded conflicting results. The absolute risk for cardiac mortality and morbidity during and after non-cardiac surgery varies between patient groups defined by surgical risk categories, making it difficult to establish a risk:benefit ratio. We discuss the hypothesis that the protective effect of β-blockers on cardiovascular outcome differs across the different risk classes of surgical procedures, thereby explaining the conflicting evidence across studies. In particular, we examine the results of a recent meta-analysis that suggests that β-blockers may reduce mortality in patients under going high-risk non-cardiac surgery.
No takes yet. Share an insight, caveat, or question.
Angeli et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: